FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020795326> ?p ?o ?g. }

• W2020795326 endingPage "238" @default.
• W2020795326 startingPage "232" @default.
• W2020795326 abstract "<i>Background:</i> Psoriasis is a typical autoimmune disease caused by a deregulation of the Th1/Th2 balance, and immunotherapy for psoriasis has been shown to be clinically efficacious. Vascular endothelial growth factor (VEGF) is a potent mediator of angiogenesis. Evidence suggests that the chronic delivery of VEGF to the skin can result in a profound inflammatory condition with many of the cellular and molecular hallmarks of human psoriasis. In this study, we investigated whether the transgenic VEGF mouse is a suitable model for antipsoriatic studies. <i>Aim:</i> To determine the effect of a recombinant murine interleukin 4 (rmIL-4) in the transgenic VEGF mouse model. <i>Methods:</i> Fifteen homozygous K14-VEGF transgenic mice were injected subcutaneously with rmIL-4 protein for 30 consecutive days with a prospective dose escalation of 0.5, 2 or 5 μg/kg. Hematoxylin-eosin staining, immunohistochemistry and real-time polymerase chain reaction analyses were performed with ear samples. <i>Results:</i> The rmIL-4 protein therapy was well tolerated. Tissue sections from treated skin showed improvements upon morphological and histological examinations: diminution of erythematous appearance and regression of epidermal thickness were observed, and T lymphocyte infiltration decreased significantly. The expressions of adhesion molecules, such as vascular cell adhesion molecule 1 and intracellular adhesion molecule 1, were found reduced. The level of IL-4 mRNA also increased while the level of γ-interferon mRNA decreased, resulting in a 10-fold increase in the ratio of Th1/Th2. <i>Conclusions:</i> Our results reveal that rmIL-4 has clinical efficacy for the treatment of K14-VEGF transgenic mice. Angiogenesis and inflammation were ameliorated by therapy with rmIL-4." @default.
• W2020795326 created "2016-06-24" @default.
• W2020795326 creator A5000186326 @default.
• W2020795326 creator A5007016148 @default.
• W2020795326 creator A5013468533 @default.
• W2020795326 creator A5021527564 @default.
• W2020795326 creator A5026804113 @default.
• W2020795326 creator A5080394822 @default.
• W2020795326 creator A5081333579 @default.
• W2020795326 creator A5090403310 @default.
• W2020795326 date "2009-01-01" @default.
• W2020795326 modified "2023-10-16" @default.
• W2020795326 title "Recombinant Murine Interleukin 4 Protein Therapy for Psoriasis in a Transgenic VEGF Mouse Model" @default.
• W2020795326 cites W1482408448 @default.
• W2020795326 cites W1965621019 @default.
• W2020795326 cites W1966248625 @default.
• W2020795326 cites W1991823448 @default.
• W2020795326 cites W1995117548 @default.
• W2020795326 cites W1999944301 @default.
• W2020795326 cites W2000292756 @default.
• W2020795326 cites W2007769122 @default.
• W2020795326 cites W2008419958 @default.
• W2020795326 cites W2015681660 @default.
• W2020795326 cites W2019583759 @default.
• W2020795326 cites W2022936031 @default.
• W2020795326 cites W2024387258 @default.
• W2020795326 cites W2035371785 @default.
• W2020795326 cites W2043427914 @default.
• W2020795326 cites W2047093890 @default.
• W2020795326 cites W2074527653 @default.
• W2020795326 cites W2080090843 @default.
• W2020795326 cites W2085396070 @default.
• W2020795326 cites W2104632655 @default.
• W2020795326 cites W2108300022 @default.
• W2020795326 cites W2118378313 @default.
• W2020795326 cites W2120822810 @default.
• W2020795326 cites W32167704 @default.
• W2020795326 cites W42371937 @default.
• W2020795326 doi "https://doi.org/10.1159/000235974" @default.
• W2020795326 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19729876" @default.
• W2020795326 hasPublicationYear "2009" @default.
• W2020795326 type Work @default.
• W2020795326 sameAs 2020795326 @default.
• W2020795326 citedByCount "18" @default.
• W2020795326 countsByYear W20207953262013 @default.
• W2020795326 countsByYear W20207953262014 @default.
• W2020795326 countsByYear W20207953262015 @default.
• W2020795326 countsByYear W20207953262017 @default.
• W2020795326 countsByYear W20207953262018 @default.
• W2020795326 countsByYear W20207953262019 @default.
• W2020795326 countsByYear W20207953262020 @default.
• W2020795326 countsByYear W20207953262022 @default.
• W2020795326 crossrefType "journal-article" @default.
• W2020795326 hasAuthorship W2020795326A5000186326 @default.
• W2020795326 hasAuthorship W2020795326A5007016148 @default.
• W2020795326 hasAuthorship W2020795326A5013468533 @default.
• W2020795326 hasAuthorship W2020795326A5021527564 @default.
• W2020795326 hasAuthorship W2020795326A5026804113 @default.
• W2020795326 hasAuthorship W2020795326A5080394822 @default.
• W2020795326 hasAuthorship W2020795326A5081333579 @default.
• W2020795326 hasAuthorship W2020795326A5090403310 @default.
• W2020795326 hasConcept C125473707 @default.
• W2020795326 hasConcept C126322002 @default.
• W2020795326 hasConcept C142724271 @default.
• W2020795326 hasConcept C153911025 @default.
• W2020795326 hasConcept C167734588 @default.
• W2020795326 hasConcept C203014093 @default.
• W2020795326 hasConcept C204232928 @default.
• W2020795326 hasConcept C2777025900 @default.
• W2020795326 hasConcept C2778690821 @default.
• W2020795326 hasConcept C2780394083 @default.
• W2020795326 hasConcept C2780564577 @default.
• W2020795326 hasConcept C71924100 @default.
• W2020795326 hasConcept C74172505 @default.
• W2020795326 hasConcept C86803240 @default.
• W2020795326 hasConceptScore W2020795326C125473707 @default.
• W2020795326 hasConceptScore W2020795326C126322002 @default.
• W2020795326 hasConceptScore W2020795326C142724271 @default.
• W2020795326 hasConceptScore W2020795326C153911025 @default.
• W2020795326 hasConceptScore W2020795326C167734588 @default.
• W2020795326 hasConceptScore W2020795326C203014093 @default.
• W2020795326 hasConceptScore W2020795326C204232928 @default.
• W2020795326 hasConceptScore W2020795326C2777025900 @default.
• W2020795326 hasConceptScore W2020795326C2778690821 @default.
• W2020795326 hasConceptScore W2020795326C2780394083 @default.
• W2020795326 hasConceptScore W2020795326C2780564577 @default.
• W2020795326 hasConceptScore W2020795326C71924100 @default.
• W2020795326 hasConceptScore W2020795326C74172505 @default.
• W2020795326 hasConceptScore W2020795326C86803240 @default.
• W2020795326 hasIssue "3" @default.
• W2020795326 hasLocation W20207953261 @default.
• W2020795326 hasLocation W20207953262 @default.
• W2020795326 hasOpenAccess W2020795326 @default.
• W2020795326 hasPrimaryLocation W20207953261 @default.
• W2020795326 hasRelatedWork W2017423448 @default.
• W2020795326 hasRelatedWork W2070430545 @default.
• W2020795326 hasRelatedWork W2347638186 @default.
• W2020795326 hasRelatedWork W2391784904 @default.

• next